The Global. The FDA has taken a step further in the regulation of biosimilar medicines with the publication of draft guidance on the labeling of these products. In this way, the North American agency rules out, as requested by the brand companies, that the data from the clinical trials used to prove the similarity of the biosimilars to the reference biologics have to appear on the product labeling.